PanCareFollowUp recommendations for surveillance of late effetcs
- Alopecia
- Cancer-related fatigue
- Cardiac problems
- Central precocious puberty (CPP)
- Cerebrovascular problems
- Chronic pain
- Coronary artery disease
- Craniofacial growth problems
- Dental and oral problems
- Dyslipidaemia
- Ear problems
- Eye problems
- Gastro-intestinal problems
- Health promotion
- Higher risk groups
- Hypertension
- Hypothalamic-pituitary (HP) axis problems
- Impaired glucose metabolism and diabetes mellitus
- Late liver injury
- Lower urinary tract problems
- Male fertility problems and sexual dysfunction
- Mental health problems
- Neurocognitive problems
- Obstetric problems
- Osteonecrosis
- Overweight and obesity
- Peripheral neuropathy
- Premature ovarian insufficiency
- Psychosocial problems
- Pulmonary problems
- Reduced bone mineral density
- Renal problems
- Spine scoliosis and kyphosis
- Spleen problems
- Subsequent breast cancer
- Subsequent CNS neoplasms
- Subsequent colorectal cancer
- Subsequent melanoma and non-melanoma skin cancer
- Subsequent neoplasms
- Subsequent thyroid cancer
- Thyroid function problems
RENAL PROBLEMS
Consensus-based recommendation for surveillance of renal problems a
This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.
Click here, to read this recommendation in PLAIN language.
Who is at risk for renal problems?
CAYA cancer survivors treated with
- ifosfamide
- cisplatin
- carboplatin
- radiotherapy to volume exposing the kidney or urinary tract, including TBI
- nephrectomy
- HSCT
What renal problems might occur?
- Glomerular dysfunction
- Tubular dysfunction
What surveillance modality should be used and at what frequency should it be performed?
All survivors at risk:
- Glomerular function testing consisting of:
- blood testing: creatinine
- urine testing: creatinine, proteinuria
- calculation of eGFR
at least every 5 years, starting at entry into long-term follow-up.
CAYA cancer survivors treated with ifosfamide, cisplatin or carboplatin:
- Tubular function testing consisting of:
- blood testing: sodium, potassium, magnesium, phosphate, calcium, albumin
- urine testing: glucose, phosphate
at least every 5 years, starting at entry into long-term follow-up
What other advice should be given with a nephrectomy?
-
Education about caution in the use of NSAIDs
- Counselling about single kidney-related health risks
at entry into long-term follow-up and periodically
What should be done if abnormalities are identified?
-
Electrolyte supplementation as guided by serum biochemistry if an electrolyte imbalance is detected
-
Refer to a nephrologist if proteinuria and/or chronic kidney disease are identified
Disclaimer
While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.
It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.
In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.
No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.
The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.